low-dos acop-b vabe weekli chemotherapi elderli patient advanced-stag diffus large-cel lymphoma elderli patient advanced-stag diffus large-cel lymphoma dlcl under-repres clinic trial combin chemotherapi regimen treatment outcom brief weekli chemotherapi regimen elderli patient elig patient year advanced-stag dlcl mix large-cleav immunoblast large-cel advanc stage ann arbor stage iii IV stage II mass cm symptom low-dos doxorubicin cyclophosphamid vincristin bleomycin prednison ld-acop-b patient march septemb complet respons CR toxic death actuari failure-fre surviv ff disease-specif surviv dss overal surviv OS maximum follow-up year regimen etoposid doxorubicin vincristin bleomycin prednison vabe patient juli june CR toxic death actuari ff dss OS maximum follow-up year differ ff dss OS regimen vabe myelosuppress infecti complic toxic death rate similar ld-acop-b follow-up toxic 